Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Jorge E CortesTara L LinGeoffrey L UyRobert J RyanStefan FaderlJeffrey E LancetPublished in: Journal of hematology & oncology (2021)
This post hoc analysis demonstrates that CPX-351 improved quality-adjusted survival, further supporting the clinical benefit in patients with newly diagnosed high-risk/secondary acute myeloid leukemia. Trial registration This trial was registered on September 28, 2012 at www.clinicaltrials.gov as NCT01696084 ( https://clinicaltrials.gov/ct2/show/NCT01696084 ) and is complete.
Keyphrases
- newly diagnosed
- acute myeloid leukemia
- phase iii
- study protocol
- clinical trial
- phase ii
- allogeneic hematopoietic stem cell transplantation
- computed tomography
- quality improvement
- physical activity
- randomized controlled trial
- magnetic resonance imaging
- open label
- contrast enhanced
- magnetic resonance
- sleep quality
- acute lymphoblastic leukemia
- placebo controlled
- double blind